

## Bryhali<sup>™</sup> (halobetasol propionate) – New drug approval

- On November 7, 2018, <u>Bausch Health</u> and <u>Ortho Dermatologics announced</u> the FDA approval of <u>Bryhali (halobetasol propionate)</u> lotion, for the topical treatment of plaque psoriasis in adults.
- Halobetasol propionate is also available generically as a <u>cream</u> and <u>ointment</u>; and brand name 0.05% lotion (<u>Ultravate</u><sup>®</sup>). Mayne will be launching a foam formulation in early 2019.
  - Halobetasol propionate cream and ointment are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
  - Ultravate and halobetasol propionate foam are indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older.
- The efficacy of Bryhali was demonstrated in two double-blind studies conducted in 430 patients with
  moderate to severe plaque psoriasis. Patients applied Bryhali or vehicle to affected areas once daily
  for 8 weeks. The primary efficacy endpoint was the proportion of patients with treatment success at
  week 8. Treatment success was defined as at least a 2-grade improvement from baseline in
  investigator global assessment (IGA) score and an IGA score equating to clear or almost clear.
  - The IGA treatment success at week 8 in the first study was 37% for the Bryhali treated patients vs. 8% for the vehicle treated patients.
  - In the second study, the IGA treatment success at week 8 was 38% vs. 12% for the Bryhali
    and vehicle treated patients, respectively.
- Warnings and precautions of Bryhali include hypothalamic-pituitary-adrenal axis suppression, local adverse reaction, ophthalmic adverse reactions, concomitant skin infections, and allergic contact dermatitis.
- The most common adverse effects (≥ 1%) with Bryhali use were upper respiratory tract infection, application site dermatitis, and hyperglycemia.
- The recommended dosage for Bryhali is to apply a thin layer of lotion to affected areas and rub in gently once daily.
  - Treatment beyond 8 weeks is not recommended, and the total dosage should not exceed approximately 50 g per week. Treatment should be discontinued if control is achieved before 8 weeks.
  - Occlusive dressings should not be used with Bryhali unless directed by a physician.
  - Bryhali should not be used on the face, groin, or in the axillae.
  - Bryhali is not for oral, ophthalmic, or intravaginal use.
- Ortho Dermatologics plans to launch Bryhali later this month. Bryhali will be available as a 0.01% lotion.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.